Physician survey | Medical records review | |||||
---|---|---|---|---|---|---|
Characteristic | Rounds 1 & 2 (N = 301) | Round 3 (N = 152) | Total (N = 453) | Rounds 1 & 2 (N = 79) | Round 3 (N = 40) | Total (N = 119) |
Country, n (%) | ||||||
France | 89 (29.6) | 39 (25.7) | 128 (28.3) | 23 (29.1) | 11 (27.5) | 34 (28.6) |
Germany | 79 (26.2) | 43 (28.3) | 122 (26.9) | 26 (32.9) | 11 (27.5) | 37 (31.1) |
Italy | 46 (15.3) | 29 (19.1) | 75 (16.6) | 6 (7.6) | 4 (10.0) | 10 (8.4) |
Spain | 44 (14.6) | 22 (14.5) | 66 (14.6) | 8 (10.1) | 4 (10.0) | 12 (10.1) |
Czech Republic | 18 (6.0) | 6 (3.9) | 24 (5.3) | 5 (6.3) | 3 (7.5) | 8 (6.7) |
Belgium | 6 (2.0) | 6 (3.9) | 12 (2.6) | 3 (3.8) | 3 (7.5) | 6 (5.0) |
Denmark | 5 (1.7) | 2 (1.3) | 7 (1.5) | 3 (3.8) | 1 (2.5) | 4 (3.4) |
Netherlands | 9 (3.0) | 3 (2.0) | 12 (2.6) | 2 (2.5) | 1 (2.5) | 3 (2.5) |
Sweden | 5 (1.7) | 2 (1.3) | 7 (1.5) | 3 (3.8) | 2 (5.0) | 5 (4.2) |
Type of institution, n (%) | ||||||
General or regional hospital | 91 (30.2) | 42 (27.6) | 133 (29.4) | 20 (25.3) | 12 (30.0) | 32 (26.9) |
Oncology clinic/institute | 30 (10.0) | 9 (5.9) | 39 (8.6) | 7 (8.9) | 5 (12.5) | 12 (10.1) |
Private clinic/hospital | 50 (16.6) | 25 (16.4) | 75 (16.6) | 33 (41.8) | 11 (27.5) | 44 (37.0) |
University or teaching/training hospital | 125 (41.5) | 70 (46.1) | 195 (43.0) | 13 (16.5) | 7 (17.5) | 20 (16.8) |
Other | 5 (1.7) | 6 (3.9) | 11 (2.4) | 6 (7.6) | 5 (12.5) | 11 (9.2) |
Size of institution, no. of inpatient bedsa | 493.6 (465.6) | 623.9 (434.5) | 538.2 (475.6) | 316.9 (525.4) | 640.2 (570.7) | 422.6 (559.0) |
Mean (SD) | 400.0 | 500.0 | 500.0 | 50.0 | 455.0 | 250.0 |
Median (Q1–Q3) | (100.0–772.5) | (310.0–895.5) | (150.0–800.0) | (17.0–400.0) | (250.0–750.0) | (23.0–625.0) |
Size of oncology dept., no. of inpatient bedsa | 39.2 (51.4) | |||||
Mean (SD) | NR | 38.6 (58.5) | – | NR | 30.0 | – |
Median (Q1–Q3) | NR | 24.5 (14.0–45.0) | – | NR | (15.0–40.0) | – |
No. of years’ experience as a practising oncologist specialising in mCRC | ||||||
Mean (SD) | 12.5 (7.1) | 13.1 (6.7) | 12.7 (7.0) | 15.7 (8.5) | 13.9 (5.9) | 15.1 (7.7) |
Median (Q1–Q3) | 11.0 (7.0–16.0) | 12.0 (8.0–18.0) | 12.0 (7.0–17.0) | 15.0 (10.0–20.0) | 14.0 (10.0–17.5) | 15.0 (10.0–20.0) |
No. of patients with mCRC treated by the oncologist in the previous 3 months | ||||||
Mean (SD) | 59.0 (57.7) | 53.1 (44.6) | 57.1 (53.7) | 58.0 (69.0) | 37.5 (54.9) | 51.1 (65.1) |
Median (Q1–Q3) | 40.0 (25.0–70.0) | 40.0 (30.0–60.0) | 40.0 (25.0–65.0) | 36.0 (20.0–70.0) | 28.0 (20.0–40.0) | 30.0 (20.0–50.0) |
No. of patients with mCRC treated with panitumumab in the last 6 months | ||||||
Mean (SD) | NR | NR | NR | 9.2 (9.1) | 6.7 (5.6) | 8.4 (8.2) |
Median (Q1–Q3) | NR | NR | NR | 6.0 (5.0–10.0) | 5.0 (3.0–9.0) | 6.0 (5.0–10.0) |